The SNAP trial: A randomised placebo-controlled trial of nicotine replacement therapy in pregnancy – Clinical effectiveness and safety until 2 years after delivery, with economic evaluation
Citation: Health Technology Assessment, 2014, vol./is. 18/54(1-128), 1366-5278;2046-4924 (2014)
Author(s): Cooper S.; Lewis S.; Thornton J.G.; Marlow N.; Watts K.; Britton J.; Grainge M.J.;
Taggar J.; Essex H.; Parrott S.; Dickinson A.; Whitemore R.; Coleman T; Coughtrie M.;
Mannion C.; et al
East Cheshire Trust (Macclesfield Hospital) participated as a source of recruitment.
Abstract: Smoking during pregnancy causes many adverse pregnancy and birth outcomes. Nicotine replacement therapy (NRT) is effective for cessation outside pregnancy but efficacy and safety in pregnancy are unknown. We hypothesised that NRT would increase smoking cessation in pregnancy without adversely affecting infants.
Objectives: To compare (1) at delivery, the clinical effectiveness and cost-effectiveness for achieving biochemically validated smoking cessation of NRT patches with placebo patches in pregnancy and (2) in infants at 2 years of age, the effects of maternal NRT patch use with placebo patch use in pregnancy on behaviour, development and disability.
Design: Randomised, placebo-controlled, parallel-group trial and economic evaluation
with follow-up at 4 weeks after randomisation, delivery and until infants were 2 years old.